Sorry, you need to enable JavaScript to visit this website.

DILANTIN‌-125® (phenytoin) Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DILANTIN-125® safely and effectively. See full prescribing information for DILANTIN-125®.

DILANTIN-125® (phenytoin) oral suspension
Initial U.S. Approval: 1953

RECENT MAJOR CHANGES

Warnings and Precautions (5.3)7/2019
Warnings and Precautions (5.6)10/2018
Warnings and Precautions (5.7)7/2019

INDICATIONS AND USAGE

DILANTIN is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. (1)

DOSAGE AND ADMINISTRATION

  • Adult starting dose in patients who have received no previous treatment is 5mL three times daily, with dose adjustments as necessary, up to 25 mL daily. (2.2)
  • Pediatric starting dose is 5 mg/kg/day in two to three equally divided doses, with dosage adjustments as necessary, up to a maximum of 300 mg daily. Maintenance dosage is 4 to 8 mg/kg/day. (2.3)
  • Serum blood level determinations may be necessary for optimal dosage adjustments—the clinically effective serum total concentration is 10 to 20 mcg/mL (unbound phenytoin concentration is 1 to 2 mcg/mL). (2.1)

DOSAGE FORMS AND STRENGTHS

DILANTIN-125 is available as a 125 mg phenytoin/5 mL oral suspension. (3)

CONTRAINDICATIONS

  • Hypersensitivity to phenytoin, its ingredients, or other hydantoins (4, 5.5)
  • A history of prior acute hepatotoxicity attributable to phenytoin (4, 5.8)
  • Coadministration with delavirdine (4)

WARNINGS AND PRECAUTIONS

  • Withdrawal Precipitated Seizure: May precipitate status epilepticus. Dose reductions or discontinuation should be done gradually. (5.1)
  • Suicidal Behavior and Ideation: Monitor patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. (5.2)
  • Serious Dermatologic Reactions: Discontinue DILANTIN at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered. (5.3)
  • Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: If signs or symptoms of hypersensitivity are present, evaluate the patient immediately. Discontinue if an alternative etiology cannot be established. (5.4)
  • Cardiac Effects: Bradycardia and cardiac arrest have been reported. (5.6)
  • Angioedema: Discontinue immediately if symptoms of angioedema such as facial, perioral, or upper airway swelling occur. (5.7)
  • Hepatic Injury: Cases of acute hepatotoxicity have been reported with DILANTIN. If this occurs, immediately discontinue. (4, 5.8)
  • Hematopoietic Complications: If occurs, follow-up observation is indicated and an alternative antiepileptic treatment should be used. (5.9)

ADVERSE REACTIONS

The most common adverse reactions are nervous system reactions, including nystagmus, ataxia, slurred speech, decreased coordination, somnolence, and mental confusion. (6)


To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Multiple drug interactions because of extensive plasma protein binding, saturable metabolism and potent induction of hepatic enzymes (7.1, 7.2).

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Prenatal exposure may increase the risks for congenital malformations and other adverse developmental outcomes. (5.13, 8.1)
  • Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients (8.6).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 7/2019

What's New

No Current Announcements.

Search

Please enter your search term(s) for DILANTIN‌-125®